Friday, 07 January 2011 08:46

Reagent Proteins Making Conference Exhibiting Debut, Dr. Retallack to Speak at Annual Peptalk Conf.

Reagent Proteins, a new division of Pfenex Inc., will be making its conference exhibiting debut at the 10th Annual PepTalk Conference in San Diego next week. In addition, Pfenex Inc. also announced that Dr. Diane Retallack, Director of Molecular Biology, will be a featured speaker at the event.

Representing both Pfenex Inc, and its Reagent Proteins division, Dr. Retallack will be providing a detailed presentation on the rapid production of high quality proteins enabled by the Pfenex Expression Technology platform. Conference attendees are encourage to attend the talk scheduled for Wednesday, January 12, 2011 at 11:45 am as part of the Higher-Throughput Protein Expression, Choosing, Designing, and Optimizing Hosts and Platforms conference track.

The conference will be held at the historic Hotel Del Coronado in San Diego, CA and will feature a select group of speakers from academia and industry. For additional information please visit the Pfenex website.

About Reagent Proteins
Reagent Proteins is a leading supplier of reagent, pre-clinical and cGMP-grade proteins to the biopharmaceutical and vaccine development community. We ensure that scientists have ready access to a comprehensive offering of high-quality proteins to enable their development efforts to proceed efficiently. For more information, please visit www.reagentproteins.com

About Pfenex Inc.
Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information, please visit www.pfenex.com

About Cambridge Health Institute’s PepTalk Conference
CHI’s 10th Annual PepTalk event- a week-long event featuring strong scientific programming comprising fourteen conferences within topic focused pipelines. The four distinct pipelines range from applying protein discovery research, to developing downstream protein expression, characterization, formulation, and production that ultimately leads to clinical applications.
Read 1699 times Last modified on Monday, 10 January 2011 07:58

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.

Want more? Visit...

Videos

  • ICON- Partnerships 12
    ICON- Partnerships 12 Steven Cutler, Group President of ICON discusses the launch of ICON's new acquisition of Firecrest at Partnerships in Clinical Trials 2012. Facing the continuing challenge of not only monitoring and…
    Read more...
  • ICON- Partnerships 12
    ICON- Partnerships 12 Steven Cutler, Group President of ICON discusses their exciting new partnership with Roche at Partnerships In Clinical Trials 2012. Medical imaging has always been a strong department within ICON. ICON…
    Read more...
  • ERT- Partnerships 12
    ERT- Partnerships 12 John Blakely, Executive Vice President and Chief Commercial Officer for ERT discusses the new trend in clinical research at Partnerships in Clinical Trials 2012 - the melding of objective and…
    Read more...
  • Chiltern- Partnerships 12
    Chiltern- Partnerships 12 Marcelo Piccirillo, Senior Clinical Research Physician for Chiltern, discusses new trends in gastrointestinal clinical development at Partnerships in Clinical Trials 2012. Current hot spots for clinical development in the field…
    Read more...
  • Blinded Diagnostics - Partnerships 12
    Blinded Diagnostics - Partnerships 12 Paul Savuto, President and CFO, and Steven Karrupan, CEO, from Blinded Diagnostics discuss Point of Care Technology at Partnerships in Clinical Trials 2012. Point of care (or decentralized testing) offers…
    Read more...
  • American Airlines - IQPC 2011
    American Airlines - IQPC 2011 American Airlines has globally launched a passive solutions that gives a new alternative to pharmaceutical manufacturers.
    Read more...

Podcasts